A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
Completed
Bristol-Myers Squibb
Phase 2
2005-04-01
The purpose of this clinical research study is to assess the safety of, exposure to, and
biological effects of BMS-512148 in stable Type 2 diabetic subjects
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
Completed
AstraZeneca
Phase 2
2005-04-01
The purpose of this clinical research study is to assess the safety of, exposure to, and
biological effects of BMS-512148 in stable Type 2 diabetic subjects
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
Completed
Bristol-Myers Squibb
Phase 2
2005-12-01
The purpose of this clinical research study is to learn if BMS-512148 is effective in
controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients
who have been diagnosed with Type 2 diabetes. Patients should first try to control their
diabetes with diet and exercise and should not have previously been treated for their
diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be
studied
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
Completed
AstraZeneca
Phase 2
2005-12-01
The purpose of this clinical research study is to learn if BMS-512148 is effective in
controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients
who have been diagnosed with Type 2 diabetes. Patients should first try to control their
diabetes with diet and exercise and should not have previously been treated for their
diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be
studied
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
Completed
Bristol-Myers Squibb
Phase 2/Phase 3
2006-10-01
The purpose of this clinical research study is to learn if BMS-512148, added to insulin and
one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can
help reduce the blood sugar levels compared to insulin and one or two anti-diabetes
medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2
diabetes. The safety of this treatment will also be studied.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
